<DOC>
	<DOCNO>NCT00101205</DOCNO>
	<brief_summary>This phase I trial study side effect best dose oxaliplatin etoposide treat young patient recurrent refractory solid tumor lymphomas . Drugs use chemotherapy , oxaliplatin etoposide , work different way stop growth cancer cell , either kill cell stop dividing . Oxaliplatin may also help etoposide work well make cancer cell sensitive drug . Giving oxaliplatin together etoposide may kill cancer cell .</brief_summary>
	<brief_title>Oxaliplatin , Ifosfamide Etoposide Treating Young Patients With Recurrent Refractory Solid Tumors Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose oxaliplatin etoposide pediatric patient recurrent refractory solid tumor lymphoma . II . Determine dose-limiting toxic effect regimen patient . SECONDARY OBJECTIVES : I . Determine pharmacokinetic profile regimen patient . II . Correlate extent oxaliplatin etoposide exposure toxic effect therapeutic effect regimen patient . III . Determine , preliminarily , antitumor activity regimen patient . OUTLINE : This dose-escalation study . Patients receive oxaliplatin IV 2 hour day 1 etoposide IV 1 hour day 1-3 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos oxaliplatin etoposide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Life expectancy &gt; 8 week Albumin &gt; 2 g/dL Histologically confirm diagnosis 1 following : solid tumor ; histologic verification require brainstem tumor optic pathway tumor ; lymphoma ; recurrent refractory conventional therapy OR know effective therapy exist ; bone marrow involvement allow Performance Status : Karnofsky &gt; = 50 % ( patient &gt; 10 year age ) OR Lansky &gt; = 50 % ( patient = &lt; 10 year age ) Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm^3 ( transfusion independent ) Hemoglobin &gt; 8 g/dL ( transfusion allow ) ALT &lt; 5.0 time ULN Creatinine normal OR glomerular filtration rate &gt; = 80 mL/min/1.73 m^2 Calcium normal ( electrolyte supplement allow ) Echocardiogram EKG normal Shortening fraction &gt; = 27 % OR ejection fraction &gt; 50 % No evidence dyspnea rest No exercise intolerance Pulse oximetry &gt; 94 % room air Neurologic deficit due CNS tumor must relatively stable &gt; = 2 week study entry Seizure disorder allow provide wellcontrolled nonenzymeinducing anticonvulsant No peripheral neurotoxicity &gt; grade 1 Sodium , potassium , magnesium normal ( electrolyte supplement allow ) At least 1 week since prior biologic agent More 1 week since prior growth factor More 6 month since prior allogeneic peripheral blood stem cell transplantation AND active graftversushost disease More 3 week since prior myelosuppressive chemotherapy ( 6 week nitrosoureas ) More 2 week since prior focal radiotherapy symptomatic metastatic site More 6 week since prior substantial bone marrow radiotherapy More 3 month since prior craniospinal ( &gt; 24 Gy ) , whole pelvis , totalbody radiotherapy Recovered prior therapy No concurrent enzymeinducing anticonvulsant , include , limited , follow : Barbiturates ; Phenytoin ; Carbamazepine Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection No history lifethreatening hypersensitivity platinumcontaining agent No prior oxaliplatin No concurrent investigational agent No concurrent anticancer therapy Inability unwillingness research participant legal guardian/representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>